Receive our newsletter – data, insights and analysis delivered to you
  1. Project
7 December 2021

Ypsomed Production Facility, Schwerin, Germany

Switzerland-based medical technology company Ypsomed is building a production facility at the Schwerin industrial park in Germany.
A ground-breaking ceremony for the construction of Ypsomed’s new production facility was held in September 2017. Credit: Ypsomed.
Ypsomed’s facility will manufacture injection and infusion systems. Credit: IE Engineering Group.
The Schwerin facility will have a 19,000m² total floor space. Credit: Ypsomed.

Switzerland-based medical technology company Ypsomed is building a production facility at the Schwerin industrial park in Germany.

The facility will operate alongside Ypsomed’s existing production sites in Switzerland, which are currently operating at full capacity. The company’s existing facilities have already been expanded and have no scope for further capacity expansions beyond 2020.

A ground-breaking ceremony for the facility’s construction took place in September 2017. Construction work is expected to be completed within 18 months, with operations scheduled to begin in the first half of 2019.

Ypsomed is investing Sfr100m ($102.29m) in the project, with the facility’s construction estimated to cost €50m ($59.94m) and the production equipment estimated to cost a further €50m ($59.94m).

The project will initially create 150 jobs over five years, with additional jobs to be created as production at the facility increases.

Ypsomed production facility location

The production facility is being developed in the Schwerin industrial park, located between Hamburg and Berlin. The park has good infrastructure and is located in close proximity to the port of Hamburg, which provides shorter trading routes.

“Construction work is expected to be completed within 18 months, with operations scheduled to begin in the first half of 2019.”

The industrial park provides facilities for multi-faceted industrial applications and offers several advanced technologies, from primary production to successful distribution. The location also has an ample pool of qualified labour.

Details of Ypsomed’s Schwerin facility

The production facility is being developed on a 100,000m² site, which will include a production and administration building with a 19,000m² total floor space. It will also have the option to expand by a further 100,000m² in the future.

A logistics warehouse will also be available, as will quality control and technical maintenance facilities.

The facility’s single-storey production space will include a cleanroom, storage facilities and a tool store. It will also include a two-storey administrative area equipped with offices, meeting rooms and an auditorium.

Equipment and products at the facility

The new facility will be equipped with plastic injection moulding equipment, printing facilities, and automated assembly and packaging equipment.

It will manufacture Ypsomed’s existing products, which are currently being produced at the company’s other sites in Switzerland. These include injection and infusion systems, and infusion sets for insulin pumps such as pens, auto-injectors and pump systems, which will be assembled, along with supplier parts to form finished end products.

The Schwerin facility will also allow Ypsomed to expand its UnoPen™ and the YpsoMate® autoinjector production capacities.

Specialist personnel employed at the facility will be trained in Switzerland.

Contractors involved in the project

Munich-based industrial design specialist IE Plast is responsible for the planning and realisation of the production facility. IE Plast’s contractual scope includes the operation, building and qualification of the facility.

Marketing commentary on Ypsomed

Ypsomed is a self-care medication solutions provider created following the split of Disetronic Group in 2003.

In 2003, the co-founder and major stakeholder in Disetronic Holding sold the company, along with its infusion systems division, to Roche. The injection systems division, however, was retained and eventually became an independent company named Ypsomed.

Products manufactured by Ypsomed at its Switzerland facilities include the ServoPen, UnoPen, YpsoMate, YpsoPen, FixPen, VerioJect and LyoTwist.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU